Denys, Gerald A.Pillar, Chris M.Sahm, Daniel F.O'Hanley, PeterStephens, Jackson T. Jr2016-03-212016-03-212014-08Denys, G. A., Pillar, C. M., Sahm, D. F., O’Hanley, P., & Stephens, J. T. (2014). Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens. Antimicrobial Agents and Chemotherapy, 58(8), 4911–4914. http://doi.org/10.1128/AAC.03020-14https://hdl.handle.net/1805/8961This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from <0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.en-USPublisher PolicyAnti-Infective AgentsDrug Resistance, Multiple, BacterialGlucose OxidaseGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansHydrogen PeroxideHypochlorous AcidLongitudinal StudiesMicrobial Sensitivity TestsOxidation-ReductionPeroxidasePharmaceutical SolutionsSinglet OxygenArticle